Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n, γ)177Lu

Applied Radiation and Isotopes

Volumn 66, Issue 2, 2008, Pages 147-151

  Dvorakova, Z ^a   Henkelmann, R ^a   Lin, X ^a   Turler A ^a   Gerstenberg, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

177Lu; Irradiation yield; Radionuclide production; Reactor neutron spectrum; Westcott convention

Indexed keywords

IRRADIATION YIELD; NEUTRON ACTIVATION; RADIONUCLIDE PRODUCTION; REACTOR NEUTRON SPECTRUM; WESTCOTT CONVENTION;

CHEMICAL STABILITY; LUTETIUM; NEUTRON FLUX; NUCLEAR MEDICINE; RADIOISOTOPES; THERMAL EFFECTS;

NUCLEAR REACTORS;

LUTETIUM 176; LUTETIUM 177; RADIOISOTOPE; UNCLASSIFIED DRUG; LUTETIUM; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CALCULATION; COMPARATIVE STUDY; EXPERIMENTAL STUDY; FRM II REACTOR; IRRADIATION; KNOWLEDGE; MONITORING; NEUTRON ACTIVATION ANALYSIS; NEUTRON RADIATION; NUCLEAR REACTOR; PRIORITY JOURNAL; TEMPERATURE; ISOLATION AND PURIFICATION;

LUTETIUM; NEUTRON ACTIVATION ANALYSIS; NUCLEAR REACTORS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 37149049104     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2007.08.013     Document Type: Article

References (29)

1. Balasubramanian P.S. Separation of carrier-free lutetium-177 from neutron irradiated natural ytterbium target. J. Radioanal. Nucl. Chem. 185 (1994) 305-310
2. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23 (2005) 4591-4601
3. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isot. 57 (2002) 177-184
4. 177Lu in medium flux reactor. Appl. Radiat. Isot. 65 (2007) 301-308
5. 0 standardization of neutron activation analysis. Atomic Data Nucl. Data Tables 85 (2003) 47-67
6. Firestone R.B., Shirley V.S., Baglin C.M., Chu S.Y.F., and Zipkin J. Table of Isotopes. eighth ed. (1996), Wiley, New York
7. 177Lu-DOTA-Rituximab. Sweiz. Med. Forum 51/52, 1266-1268.
8. 177Lu process. J. Radioanal. Nucl. Chem. 255 (2003) 575-579
9. Høgdahl, O.T., 1962. Neutron absorption in pile neutron activation analysis. Report MMPP-226-1, Michigan Memorial Phoenix Project, University of Michigan, Ann Arbor.
10. Høgdahl, O.T., 1965. In: Proceedings of the Symposium on Radiochemical Methods of Analysis, vol. 1, Salzburg 1964, International Atomic Energy Agency, Vienna, p. 23.
11. Holden N.E. Temperature dependence of the Westcott g-factor for neutron reactions in activation analysis. Pure Appl. Chem. 71 (1999) 2309-2315
12. 176Yb targets. Appl. Radiat. Isot. 63 (2005) 23-36
13. Knapp, F.F., Ambrose, K.R., Beets, A.L., Luo, H., McPherson, D.W., Mirzadeh, S., 1996. Nuclear medicine program progress report for quarter ending September 30, 1995. ORNL/TM-13107.
14. Kondev F.G. Nuclear data sheets for A = 177. Nucl. Data Sheets 98 (2003) 801-1095
15. 0]octreotide in patients. Eur. J. Nucl. Med. 28 (2001) 1319-1325
16. 177Lu process. Appl. Radiat. Isot. 53 (2000) 421-425
17. Lin X., Baumgärtner F., and Li X. The program "MULTINAA" for various standardization methods in neutron activation analysis. J. Radioanal. Nucl. Chem. 215 (1997) 179-191
18. Lin X., Henkelmann R., Türler A., Gerstenberg H., and De Corte F. Neutron flux parameters at irradiation positions in the new research reactor FRM-II. Nucl. Instrum. Methods Phys. Res. Sect. A 564 (2006) 641-644
19. Meredith R.F., Alvarez R.D., Partridge E.E., Khazaeli M.B., Lin Ch.Y., Macey D.J., Maxwell Austin J., Kilgore L.C., Grizzle W.E., Schlom J., and LoBuglio A.F. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother. Radiopharm. 16 (2001) 305-315
20. 177Lu of specific activity and purity suitable for medical applications. J. Radioanal. Nucl. Chem. 257 (2003) 53-57
21. 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 29 (2002) 431-442
22. Mughabghab S.F. Neutron Cross Sections, Part B, Z = 61 - 100 (1984), Academic Press, New York
23. 177Lu for radionuclide therapy. Appl. Radiat. Isot. 59 (2003) 109-118
24. Qaim S.M. Therapeutic radionuclides and nuclear data. Radiochim. Acta 89 (2001) 297-302
25. 3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother. Radiopharm. 18 (2003) 593-599
26. Rutty Solá G.A., Argüelles M.G., Bottazzini D.L., Furnari J.C., Gomez Parada I., Rojo A., and Vera Ruiz H. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and pre-clinical studies. Radiochim. Acta 88 (2000) 157-161
27. 131I. J. Nucl. Med. 42 (2001) 967-974
28. 3]octreotate. J. Clin. Oncol. 13 (2004) 2724-2729
29. Westcott, C.H., 1960. Effective cross section values for well moderated thermal reactor spectra. Report AECL-1101, Chalk River Laboratory, Chalk River, Ontario, Canada.